CA125 over‐release behavior following a 75‐g oral glucose test as a predictive biomarker of multidrug resistance in patients with ovarian cancer

Multidrug resistance is a major cause of death in patients with ovarian cancer. To improve patient survival, we developed a novel, noninvasive and convenient tool, the 75‐gram oral glucose (75gOG)‐stimulated CA125 test, to monitor cancer chemoresistance in real time. Our in vitro proof‐of‐principal...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of cancer 2019-09, Vol.145 (6), p.1690-1700
Hauptverfasser:	He, Yifeng, Gu, Zhuowei, Zhu, Qiujing, Chen, Mo, He, Chenghui, Huang, Yuting, Li, Qing, Di, Wen
Format:	Artikel
Sprache:	eng
Schlagworte:	1-Phosphatidylinositol 3-kinase 2‐year survival Akt AKT protein Antineoplastic Agents - therapeutic use Biomarkers - metabolism Blood Glucose - metabolism CA-125 Antigen - metabolism CA125 Cancer Cell Line, Tumor Chemoresistance Cisplatin Drug Resistance, Multiple Drug Resistance, Neoplasm Female Glucose Glucose Tolerance Test GLUT4 Humans Inhibitory Concentration 50 Insulin Insulin - administration & dosage Insulin - blood Medical research Multidrug resistance Multidrug resistant organisms OGTT Ovarian cancer Ovarian carcinoma Ovarian Neoplasms - blood Ovarian Neoplasms - drug therapy Paclitaxel PI3K Prognosis Proof of Concept Study Secretion Surgery Survival Taxol
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!